Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Pancreatic Cancer Metastatic 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 18Cisplatin 12Oxaliplatin 7pembrolizumab 6Nivolumab 6Capecitabine 4trametinib 3Fluorouracil 3Bevacizumab 3tremelimumab 2lenvatinib 2durvalumab 2derazantinib 2atezolizumab 2Trastuzumab 2Ramucirumab 2Radiofrequency Ablation 2Panitumumab 2Leucovorin 2Cryosurgery 2zanidatamab 1vandetanib 1tucatinib 1tocilizumab 1telotristat ethyl 1sargramostim 1rucaparib 1regorafenib 1pertuzumab 1milademetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Biliary Tract Neoplasms × devimistat × Clear all
NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡